Citadel Advisors’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.09M Sell
502,800
-350,200
-41% -$3.17M ﹤0.01% 4675
2025
Q4
$5.73M Sell
853,000
-286,800
-25% -$2.16M ﹤0.01% 4077
2025
Q3
$9.88M Sell
1,139,800
-102,700
-8% -$799K ﹤0.01% 3292
2025
Q2
$7.83M Buy
1,242,500
+592,000
+91% +$3.92M ﹤0.01% 3383
2025
Q1
$4.17M Sell
650,500
-414,400
-39% -$3.43M ﹤0.01% 4188
2024
Q4
$8.56M Sell
1,064,900
-138,200
-11% -$1.33M ﹤0.01% 3187
2024
Q3
$15.2M Sell
1,203,100
-208,500
-15% -$2.69M ﹤0.01% 2361
2024
Q2
$17.9M Buy
1,411,600
+643,300
+84% +$6.47M ﹤0.01% 2111
2024
Q1
$3.67M Buy
768,300
+198,800
+35% +$922K ﹤0.01% 4463
2023
Q4
$2.73M Sell
569,500
-137,700
-19% -$843K ﹤0.01% 4815
2023
Q3
$5.12M Buy
707,200
+211,600
+43% +$1.69M ﹤0.01% 3609
2023
Q2
$3.68M Sell
495,600
-190,200
-28% -$1.5M ﹤0.01% 4118
2023
Q1
$4.75M Sell
685,800
-408,800
-37% -$3.76M ﹤0.01% 3908
2022
Q4
$11.3M Buy
1,094,600
+548,700
+101% +$9.68M ﹤0.01% 2661
2022
Q3
$9.94M Sell
545,900
-909,000
-62% -$39.4M ﹤0.01% 2771
2022
Q2
$74.8M Buy
1,454,900
+193,400
+15% +$10M 0.02% 752
2022
Q1
$92.9M Sell
1,261,500
-280,500
-18% -$25M 0.02% 698
2021
Q4
$221M Buy
1,542,000
+226,200
+17% +$38.9M 0.05% 311
2021
Q3
$273M Buy
1,315,800
+185,200
+16% +$40.8M 0.06% 240
2021
Q2
$240M Buy
1,130,600
+88,800
+9% +$16.3M 0.05% 260
2021
Q1
$189M Buy
1,041,800
+146,200
+16% +$29.1M 0.05% 310
2020
Q4
$99.9M Sell
895,600
-344,400
-28% -$36.6M 0.03% 555
2020
Q3
$134M Buy
1,240,000
+936,900
+309% +$114M 0.04% 322
2020
Q2
$25.3M Buy
303,100
+162,600
+116% +$6.22M 0.01% 1296
2020
Q1
$1.91M Buy
140,500
+101,600
+261% +$860K ﹤0.01% 4215
2019
Q4
$155K Buy
38,900
+23,700
+156% +$103K ﹤0.01% 8341
2019
Q3
$76K Buy
+15,200
New +$83.2K ﹤0.01% 8592
2019
Q2
Sell
-24,745
Closed -$273K 9642
2019
Q1
$273K Buy
24,745
+11,985
+94% +$378K ﹤0.01% 7749
2018
Q4
$470K Sell
12,760
-3,420
-21% -$133K ﹤0.01% 6491
2018
Q3
$608K Buy
16,180
+4,680
+41% +$132K ﹤0.01% 6384
2018
Q2
$308K Buy
11,500
+5,285
+85% +$179K ﹤0.01% 7165
2018
Q1
$261K Sell
6,215
-1,285
-17% -$51.6K ﹤0.01% 6949
2017
Q4
$186K Buy
7,500
+805
+12% +$19.6K ﹤0.01% 7160
2017
Q3
$153K Buy
6,695
+320
+5% +$7.16K ﹤0.01% 6842
2017
Q2
$147K Buy
6,375
+2,650
+71% +$52K ﹤0.01% 6757
2017
Q1
$95K Sell
3,725
-1,585
-30% -$43.6K ﹤0.01% 6876
2016
Q4
$134K Sell
5,310
-25,515
-83% -$744K ﹤0.01% 6559
2016
Q3
$1.28M Buy
30,825
+22,630
+276% +$2.92M ﹤0.01% 3513
2016
Q2
$1.19M Buy
8,195
+3,735
+84% +$428K ﹤0.01% 3359
2016
Q1
$460K Buy
4,460
+605
+16% +$64.9K ﹤0.01% 4528
2015
Q4
$647K Sell
3,855
-1,920
-33% -$295K ﹤0.01% 4135
2015
Q3
$817K Sell
5,775
-160
-3% -$35.9K ﹤0.01% 4092
2015
Q2
$1.32M Buy
5,935
+155
+3% +$27.2K ﹤0.01% 3601
2015
Q1
$956K Buy
5,780
+2,640
+84% +$429K ﹤0.01% 3980
2014
Q4
$372K Buy
3,140
+160
+5% +$16.7K ﹤0.01% 5127
2014
Q3
$249K Buy
2,980
+1,145
+62% +$103K ﹤0.01% 5485
2014
Q2
$170K Sell
1,835
-15
-0.8% -$1.32K ﹤0.01% 5732
2014
Q1
$168K Sell
1,850
-40
-2% -$4.47K ﹤0.01% 5703
2013
Q4
$194K Buy
1,890
+915
+94% +$64.6K ﹤0.01% 5055
2013
Q3
$62K Sell
975
-290
-23% -$16.3K ﹤0.01% 5665
2013
Q2
$52K Buy
+1,265
New +$54.8K ﹤0.01% 5643

Other funds holding NVAX

Citadel Advisors's NVAX Position: Q1 2026 in Review

Citadel Advisors increased its Novavax (NVAX) stake by 4.7% in Q1 2026, buying an estimated $453K and bringing the position to 1,123,746 shares worth $9.15M. The position accounts for ﹤0.01% of the portfolio, ranked #3379.

Citadel Advisors first reported a position in NVAX in Q2 2013 and has held it in 49 quarters since. The position peaked at $145M in Q2 2021. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • Citadel Advisors held 1,123,746 shares of Novavax worth $9.15M as of Q1 2026.
  • Citadel Advisors bought 50,019 Novavax shares in Q1 2026, an estimated $453K.
  • Novavax made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3379 holding.
  • Citadel Advisors first reported a position in Novavax in Q2 2013 and has held it in 49 quarters since.
  • Citadel Advisors's Novavax position peaked at $145M in Q2 2021.
  • 257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.